Adis, Auckland, New Zealand.
Drugs. 2014 Jun;74(8):929-38. doi: 10.1007/s40265-014-0228-2.
Albiglutide (Eperzan® [EU]; Tanzeum™ [US]), a glucagon-like peptide 1 receptor agonist, has been developed by GlaxoSmithKline for the treatment of type 2 diabetes mellitus (T2DM). Albiglutide has received its first global approval in this indication in the EU, for use in combination with other antihyperglycaemic agents, including basal insulin, when these drugs and diet and exercise do not provide adequate glycaemic control, and as monotherapy in patients unable to take metformin due to contraindications or intolerance when diet and exercise alone do not provide adequate glycaemic control. Albiglutide has subsequently been approved for the second-line or later treatment of T2DM as an adjunct to diet and exercise in the US. This article summarizes the milestones in the development of albiglutide leading to this first approval for the treatment of T2DM.
阿必鲁肽（艾塞纳® [欧盟]；替西珠单抗™ [美国]），一种胰高血糖素样肽 1 受体激动剂，由葛兰素史克公司研发，用于治疗 2 型糖尿病（T2DM）。阿必鲁肽在欧盟首次获得该适应证的全球批准，可与其他抗高血糖药物联合使用，包括基础胰岛素，当这些药物、饮食和运动不能充分控制血糖时，以及在因禁忌证或不耐受而不能服用二甲双胍的患者中作为单药治疗，当饮食和运动不能充分控制血糖时。此后，阿必鲁肽在美国被批准作为饮食和运动的辅助治疗，用于 T2DM 的二线或更后线治疗。本文总结了导致阿必鲁肽首次获批用于治疗 T2DM 的开发里程碑。
